Table 1.
Clinical characteristics | Total patients | Normal-TG group | High-TG group | P-value |
---|---|---|---|---|
(n = 196) | (n = 156) | (n = 40) | ||
Age of onset, years, mean ± SD | 43.4 ± 13.6 | 43.1 ± 14.8 | 45.1 ± 13.9 | 0.43 |
Sex, female, n (%) | 124 (63.3) | 99 (63.5) | 25 (62.5) | 0.91 |
BMI, (Kg/m2), median (IQR) | 22.9 (20.4–25.4) | 22.8 (20.3–25.3) | 23.1 (20.6–25.4) | 0.86 |
TC, median (IQR), mmol/L | 4.3 (3.7–5.0) | 4.3 (3.6–4.9) | 5.0 (4.0–5.7) | 0.005* |
TG, median (IQR), mmol/L | 1.2 (0.8–1.6) | 1.0 (0.8–1.3) | 2.3 (1.9–4.1) | <0.001* |
HDL, median (IQR), mmol/L | 1.2 (1.0–1.4) | 1.3 (1.0–1.4) | 1.1 (0.9–1.2) | 0.003* |
LDL, mean ± SD, mmol/L | 2.7 (2.2–3.4) | 2.7 ± 0.6 | 3.0 ± 1.2 | 0.15 |
Glucose, median (IQR), mmol/L | 4.7 (4.2–5.7) | 4.9 (4.2–5.8) | 4.4 (4.2–5.8) | 0.55 |
Initial EDSS, median (IQR) | 4.0 (3.0–6.0) | 4.0 (3.0–6.0) | 5.0 (3.8–6.5) | 0.12 |
Anti-AQP4 status, n (%) | ||||
Negative | 29 (31.2) | 22 (29.7) | 7 (36.8) | 0.53 |
Positive | 64 (68.8) | 52 (70.3) | 12 (63.2) | 0.99 |
Hypertension, n (%) | 14 (7.1) | 10 (6.4) | 4 (10.0) | 0.49 |
Diabetes, n (%) | 9 (4.6) | 7 (4.5) | 2 (5.0) | 0.69 |
Autoimmune diseases, n (%) | 10 (5.1) | 8 (5.1) | 2 (5.0) | 0.97 |
Corticosteroid treatment, n (%) | 180 (91.8) | 143 (91.7) | 37 (92.5) | 0.86 |
Immunosuppressant treatment, n (%) | 56 (28.6) | 42 (26.9) | 14 (35.0) | 0.31 |
Rehabilitation training, n (%) | 39 (19.9) | 30 (19.2) | 9 (22.5) | 0.64 |
Statin treatment, n (%) | 21 (13.5) | 15 (9.9) | 6 (15%) | 0.48 |
Residual EDSS, median (IQR) | 1.5 (0.5–3.5) | 1.0 (0–3.0) | 2.0 (1.8–4.0) | 0.002* |
Outcomes, good recovery, n (%) | 142 (72.4) | 122 (78.2) | 20 (50.0) | 0.006* |
Relapses, n (%) | 72 (36.7) | 53 (40.0) | 19 (47.5) | 0.11 |
Interval time, month, median (IQR) | 9.2 (6.3–15.2) | 10.0 (6.3–15.0) | 7.0 (6.3–12.0) | 0.08 |
Follow-up time, month, median (IQR) | 20.5 (13.4–37.1) | 21.2 (15.0–40.4) | 20.3 (11.6–36.4) | 0.54 |
Continuous variables were presented as mean ± SD or median (IQR = 25th−75th percentile), and categorical variables were described as percentages.
Normal-TG Group, patients whose triglyceride levels were below or equal to 1.7 mmol/L; High-TG Group, patients whose triglyceride levels were higher than1.7 mmol/L.
BMI, body mass index; TC, total cholesterol; TG, triglycerides; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; AQP4, aquaporin-4; EDSS, Expanded Disability Status Scale.
p < 0.05.